Literature DB >> 16170322

Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells.

Caroline Cole1, Jian Qiao, Timothy Kottke, Rosa Maria Diaz, Atique Ahmed, Luis Sanchez-Perez, Gregory Brunn, Jill Thompson, John Chester, Richard G Vile.   

Abstract

Antigen-specific T cells circulate freely and accumulate specifically at sites of antigen expression. To enhance the survival and targeting of systemically delivered viral vectors, we exploited the observation that retroviral particles adhere nonspecifically, or 'hitchhike,' to the surface of T cells. Adoptive transfer of antigen-specific T cells, loaded with viruses encoding interleukin (IL)-12 or Herpes Simplex Virus thymidine kinase (HSVtk), cured established metastatic disease where adoptive T-cell transfer alone was not effective. Productive hand off correlated with local heparanase expression either from malignant tumor cells and/or as a result of T-cell activation by antigen, providing high levels of selectivity for viral transfer to metastatic tumors in vivo. Protection, concentration and targeting of viruses by adsorption to cell carriers represent a new technique for systemic delivery of vectors, in fully immunocompetent hosts, for a variety of diseases in which delivery of genes may be therapeutically beneficial.

Entities:  

Mesh:

Year:  2005        PMID: 16170322     DOI: 10.1038/nm1297

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  54 in total

1.  Entry kinetics and cell-cell transmission of surface-bound retroviral vector particles.

Authors:  Lee S O'Neill; Amy M Skinner; Josha A Woodward; Peter Kurre
Journal:  J Gene Med       Date:  2010-05       Impact factor: 4.565

2.  Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.

Authors:  Flavia Fontana; Raquél Bartolo; Hélder A Santos
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Prolonged adherence of human immunodeficiency virus-derived vector particles to hematopoietic target cells leads to secondary transduction in vitro and in vivo.

Authors:  Yung-Wei Pan; Jarrad M Scarlett; Tammy T Luoh; Peter Kurre
Journal:  J Virol       Date:  2006-10-11       Impact factor: 5.103

Review 4.  The status of gene therapy for brain tumors.

Authors:  Giulia Fulci; E Antonio Chiocca
Journal:  Expert Opin Biol Ther       Date:  2007-02       Impact factor: 4.388

5.  Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells.

Authors:  Nancy Y Villa; Clive H Wasserfall; Amy M Meacham; Elizabeth Wise; Winnie Chan; John R Wingard; Grant McFadden; Christopher R Cogle
Journal:  Blood       Date:  2015-04-22       Impact factor: 22.113

6.  Rapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.

Authors:  Emily J Platt; Susan L Kozak; James P Durnin; Thomas J Hope; David Kabat
Journal:  J Virol       Date:  2009-12-30       Impact factor: 5.103

Review 7.  [Combination of Oncolytic Virotherapy and CAR T/NK Cell Therapy for the Treatment of Cancer].

Authors:  G V Kochneva; G F Sivolobova; A V Tkacheva; A A Gorchakov; S V Kulemzin
Journal:  Mol Biol (Mosk)       Date:  2020 Jan-Feb

8.  Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2.

Authors:  Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Jose Pulido; Candice Willmon; Matt Coffey; Peter Selby; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

9.  Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Authors:  Timothy Kottke; Rosa M Diaz; Karen Kaluza; Jose Pulido; Feorillo Galivo; Phonphimon Wongthida; Jill Thompson; Candice Willmon; Glen N Barber; John Chester; Peter Selby; Scott Strome; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Mol Ther       Date:  2008-09-30       Impact factor: 11.454

10.  Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Authors:  E J Ilett; R J Prestwich; T Kottke; F Errington; J M Thompson; K J Harrington; H S Pandha; M Coffey; P J Selby; R G Vile; A A Melcher
Journal:  Gene Ther       Date:  2009-03-12       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.